A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
Public ClinicalTrials.gov record NCT00988052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS
Study identification
- NCT ID
- NCT00988052
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 839 participants
Conditions and interventions
Conditions
Interventions
- Laquinimod Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2009
- Primary completion
- Jun 30, 2017
- Completion
- Jun 30, 2017
- Last update posted
- Dec 8, 2021
2009 – 2017
United States locations
- U.S. sites
- 20
- U.S. states
- 18
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 1076 | Phoenix | Arizona | 85004 | — |
| Teva Investigational Site 1090 | Centennial | Colorado | 80112 | — |
| Teva Investigational Site 1088 | Fort Collins | Colorado | 80528 | — |
| Teva Investigational Site 1102 | Northbrook | Illinois | 60062 | — |
| Teva Investigational Site 1081 | Fort Wayne | Indiana | 46845 | — |
| Teva Investigational Site 1083 | Des Moines | Iowa | 50314 | — |
| Teva Investigational Site 1086 | Kansas City | Kansas | 66103 | — |
| Teva Investigational Site 1101 | Lexington | Kentucky | 40513 | — |
| Teva Investigational Site 1096 | Farmington Hills | Michigan | 48334 | — |
| Teva Investigational Site 1093 | Minneapolis | Minnesota | 55414 | — |
| Teva Investigational Site 1098 | St Louis | Missouri | 63104 | — |
| Teva Investigational Site 1082 | New York | New York | 10016 | — |
| Teva Investigational Site 1073 | Winston-Salem | North Carolina | 27157 | — |
| Teva Investigational Site 1097 | Fargo | North Dakota | 58103 | — |
| Teva Investigational Site 1084 | Dayton | Ohio | 45417 | — |
| Teva Investigational Site 1092 | Oklahoma City | Oklahoma | 73120 | — |
| Teva Investigational Site 1100 | Hershey | Pennsylvania | 17033-0850 | — |
| Teva Investigational Site 1075 | Lubbock | Texas | 79410 | — |
| Teva Investigational Site 1078 | San Antonio | Texas | 78231 | — |
| Teva Investigational Site 1085 | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 115 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00988052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2021 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00988052 live on ClinicalTrials.gov.